The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.
about
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitisChallenges and approaches for the development of safer immunomodulatory biologics.Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.In Vitro Skin Models and Their Predictability in Defining Normal and Disease Biology, Pharmacology, and Toxicity.Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
P2860
The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The yin and yang of immunomodu ...... ance between benefit and risk.
@en
The yin and yang of immunomodu ...... ance between benefit and risk.
@nl
type
label
The yin and yang of immunomodu ...... ance between benefit and risk.
@en
The yin and yang of immunomodu ...... ance between benefit and risk.
@nl
prefLabel
The yin and yang of immunomodu ...... ance between benefit and risk.
@en
The yin and yang of immunomodu ...... ance between benefit and risk.
@nl
P2860
P356
P1476
The yin and yang of immunomodu ...... ance between benefit and risk.
@en
P2093
Dimitry M Danilenko
P2860
P304
P356
10.1177/0192623311430237
P407
P577
2012-01-05T00:00:00Z